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Background: The insertion of central venous access devices, such as totally implantable venous access ports
(TIVAPs), is routine in patients who need a safe and permanent venous access. The number of port implantations is
increasing due to the development of innovative adjuvant and neo-adjuvant therapies. Currently, two different strategies
are being routinely used: surgical cut-down of the cephalic vein (vena section) and direct puncture of the subclavian
vein. The aim of this trial is to identify the strategy for the implantation of TIVAPs with the lowest risk of pneumothorax
and haemothorax.
Methods/Design: The PORTAS-3 trial is designed as a multicentre, randomised controlled trial to compare two
implantation strategies. A total of 1,154 patients will be randomised after giving written informed consent. Patients
must be over 18 years of age and scheduled for primary implantation of a TIVAP on the designated side. The primary
endpoint will be the frequency of pneumothorax and haemothorax after insertion of a TIVAP by one of two different
strategies. The experimental intervention is as follows: open strategy, defined as surgical cut-down of the cephalic vein,
supported by a rescue technique if necessary, and in the case of failure, direct puncture of the subclavian vein. The
control intervention is as follows: direct puncture of the subclavian vein using the Seldinger technique guided by
sonography, fluoroscopy or landmark technique. The trial duration is approximately 36 months, with a recruitment
period of 18 months and a follow-up period of 30 days.
Discussion: The PORTAS-3 trial will compare two different TIVAP implantation strategies with regard to their individual
risk of postoperative pneumothorax and haemothorax. Since TIVAP implantation is one of the most common procedures
in general surgery, the results will be of interest for a large community of surgeons as well as oncologists and general
practitioners. The pragmatic trial design ensures that the results will be generalizable to a wide range of patients.
Trial registration: The trial protocol was registered on 28 August 2014 with the German Clinical Trials Register
(DRKS00004900). The World Health Organization’s Universal Trial Number is U1111-1142-4420.
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Totally implantable venous access port (TIVAP) im-
plantation was first introduced in the early 1980s by
Niederhuber et al. [1]. Following further refinement, the
technique has been adopted worldwide to create a safe
and permanent venous access for chemotherapy (CHT)
and/or parenteral nutrition. TIVAPs last longer, have
lower infection rates and are more suitable for active pa-
tients than external central venous catheters (such as the
Hickman´s catheter) [2]. The number of TIVAP inser-
tions is constantly increasing. In Germany, 480,176 new
cases of oncological diseases were diagnosed in 2010. In
2008, 80,034 TIVAP implantations were performed on
in-patients in German hospitals, and it is estimated that
more than 101,000 TIVAP implantations were performed
in an out-patient setting in 2012 [3].
The techniques most often used for insertion of
TIVAPs are surgical cut-down of the cephalic vein
((SCD) open strategy), accomplished predominantly by
surgeons, and puncture of the subclavian vein ((PSV)
closed strategy), performed by surgeons or interventional
radiologists. The median primary success rates given in
various retrospective studies and a small number of
single-centre, randomised controlled trials range from
71 to 94% for SCD, and from 90 to 99% for PSV
[2,4-13]. Common complications, such as kinking or
dislocation of the catheter, subcutaneous haematoma,
wound infection and nerve palsy, are observed with both
techniques; however, specific risks are associated only with
PSV, including the ‘pinch-off ’ phenomenon, pneumo-
thorax and haemothorax, which in most cases requires
further treatment and often admission to hospital [14-16].
In the literature, the rate of pneumothorax and haemotho-
rax after PSV is reported to be about 3%, ranging up to
6% in prospective studies [14-18]. In contrast, if SCD is
successful there is no risk for pneumothorax or haemo-
thorax; however, in some cases implantation via SCD is
not possible, so PSV is required to implant the TIVAP. If
SCD fails, a rescue technique (RT) can be executed using
a guide wire, vein dilator and peel-away sheath through
the cephalic vein to overcome narrow vessels or obstruc-
tions, thus avoiding PSV and its subsequent risks. Al-
though TIVAP implantation is one of the top 50 (surgical)
interventions in Germany, no multicentre trial comparing
these two strategies has been performed.
Methods/Design
Aim of the trial
The PORTAS-3 trial, a multicenter, randomized, con-
trolled trial comparing complication rates of open and
closed implantation strategies for insertion of a totally
implantable venous access port (TIVAP) in oncological
patients, is a pragmatic trial that aims at comparing the
open strategy (SCD and if necessary RT; if both fail,PSV) to the closed strategy (PSV) with regard to the
frequency of pneumothorax and haemothorax.Sample size
A review of the previous literature, including our own
randomised controlled trials, revealed a pneumothorax
and haemothorax rate of about 3% for placement of a
TIVAP by PSV; however, there is no risk if implantation
by SCD is successful [14-18]. SCD was successful in 71
to 94% of cases (including the RT), therefore, about
17.5% of patients underwent PSV as a secondary im-
plantation technique. Thus, the overall risk of pneumo-
thorax and haemothorax for the open strategy is about
0.5% (0.175 × 0.03). Assuming a difference of 2.5%, a trial
with a desired power of 0.9 and a type 1 error of 0.05
would need to include 577 patients per group to detect
this difference in pneumothorax and haemothorax fre-
quency when applying a chi-square test. No missing
values for the primary endpoint are assumed, so a total of
1,154 patients have to be randomised into the two inter-
vention groups. A Consolidated Standards of Reporting
Trials (CONSORT) flow chart is provided in Figure 1.Eligibility
Inclusion criteria
Only adult patients (>18 years) with an oncological dis-
ease, scheduled for primary elective TIVAP implantation
on the designated side, will be included. Furthermore, all
subjects will have to be able to understand the character
and individual consequences of this trial, and will have
to provide written informed consent before inclusion.Exclusion criteria
Patients who are participating in another interventional
trial which could interfere with the primary endpoint of
this trial will not be admitted.Subject withdrawal criteria
PORTAS-3 trial participants will be withdrawn at their
own request or if, in the investigator’s opinion, continu-
ation of the trial would be detrimental to the subject’s
wellbeing. Withdrawn patients will be included in the
final report of the trial to ensure complete transparency.Informed consent
All patients scheduled for TIVAP implantation at one of
the participating centres will be screened for eligibility
and will be informed about the PORTAS-3 trial during a
pretreatment visit. The patients will be asked to give
their informed consent after all study procedures, poten-
tial risks and benefits and the data handling have been
explained to them in detail.
Figure 1 CONSORT flow chart. cVS – classical vena section; EP – endpoint; PSV – puncture of the subclavian vein; RT – rescue technique; V – visit.
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Minimisation of systematic bias
Consecutively screened and eligible patients will be in-
cluded at each centre after initiation of the study. In
order to achieve comparable intervention groups for
known and unknown risk factors, patients will be allo-
cated randomly to the two treatment groups in bal-
anced permuted blocks, and stratified by centre using
the central web-based software “Randomizer”, pro-
vided by the Institute of Medical Informatics, Statistics
and Documentation of the Medical University of Graz.
To avoid any potential for predicting the group alloca-
tion of future patients, the block length is fixed in a
separate document that is withheld from the study
site. In addition, persons in charge of randomisation
procedures as described above will not be able to read
or edit the randomisation design chosen within the
software.Minimisation of treatment bias
Prior to study start, staff at all participating centres will
be personally trained and introduced to all study-specific
procedures during a collaborative investigator meeting.
In addition, all procedures will be predefined in a study-
specific monitoring manual. Participating centres will be
updated on a regular basis to ensure comparable treat-
ment of patients. All centres will use the same TIVAP
device (Celsite® Epoxid Port, B Braun Medical, Boulogne-
Billancourt, France). Antibiotic prophylaxis will be given
to patients at risk of endocarditis according to the local
standards and guidelines. In other cases, peri-operative
prophylactic antibiotics can be administered at the discre-
tion of the operating surgeon.
Minimisation of measurement bias
Blinding of patients and surgeons is not possible due to
the nature of the surgical procedures to be evaluated.
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to be prone to measurement bias, as pneumothorax and
haemothorax are defined exclusively and can be assessed
objectively [19].
Trial treatment
Since the PORTAS-3 trial is a pragmatic trial comparing
two surgical strategies, only the key features of the com-
pared trial treatments will be predefined by the protocol.
Apart from these key features, the interventions can be
performed according to the individual centre’s routine
and the surgeon’s standard practice. The side for TIVAP
implantation will depend on surgeon’s or patient’s pref-
erence. Factors that may influence the choice of im-
plantation side include the following: breast cancer on
one side, left- or right-handedness, left or right sub-
clavian vein is occluded by a thrombosis, patient’s wish,
previous insertion of port catheter and dialysis shunt on
the left or right arm.
All patients will be placed in a 5° reverse Trendelenburg
position. Each patient’s neck, chest and shoulders will
be prepared and draped in the customary sterile man-
ner. Antibiotic prophylaxis will be given to patients at
risk of endocarditis according to the local standards
and guidelines. In other cases, peri-operative prophy-
lactic antibiotics can be administered upon the deci-
sion of the operating surgeon. A study nurse will be
present to document the intervention. The interven-
tion will be continued in compliance with the random-
isation result.Figure 2 Photo documentation of the rescue technique. a) Ventral tran
narrow cephalic vein. c) Radiograph of intravascular course of the guide w
catheter and removal of peel-away sheath. f) Correctly placed catheter in cIntervention group A (open strategy)
Following the infiltration of local anaesthesia in sterile
fashion into the skin and subcutaneous layer, a cutane-
ous incision will be made over the deltopectoral sulcus
region to expose the cephalic vein. The cephalic vein
will be ligated distally and encircled cranially with an
resorbable suture. The vein will be transected ventrally
(Figure 2a) and the catheter, flushed with heparinised
saline, will be introduced. If simple SCD is not success-
ful, the RT will be used as a second step. Therefore,
catheter insertion will be supported by use of a guide
wire (Figure 2b, c), vein dilator and peel-away sheath
through the cephalic vein (Figure 2d). The guide wire
and dilator will be removed, and the catheter easily
introduced through the peel-away sheath, which can be
removed afterwards (Figure 2e, f ).
Correct positioning will be controlled via X-ray, fluor-
oscopy (tip of the catheter in the superior vena cava just
at the level of bronchial bifurcation) or intraatrial elec-
trocardiogram. The catheter will be connected to the
port chamber. Using the same incision, a subcutaneous
pocket will be prepared by blunt preparation on the pec-
toral fascia. The port chamber will be fixed on the fascia
of the pectoral muscle with three single non-absorbable
sutures. Wound closure will be performed in accordance
with the local standards of the trial centres. Flow for
blood withdrawal and infusion will be tested via cutane-
ous puncture (Huber needle). To complete the proced-
ure, the system will be blocked by means of saline with
or without heparin, according to the local standards.section of cephalic vein. b) Introduction of a guide wire due to
ire. d) Introduction of vein dilator and peel-away sheath. e) Insertion of
ephalic vein and fixation.
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Guidance for the puncture by means of sonography,
fluoroscopy or the landmark technique is permitted. For
fluoroscopy guidance, patients receive a peripheral ven-
ous catheter on the side of the planned puncture loca-
tion to administer the contrast agent and check that the
subclavian vein is not obstructed by a thrombosis (road-
map technique). For sonography guidance, a standard
ultrasound device can be used to visualise the subclavian
vein. The landmark technique uses anatomical land-
marks (clavicle, jugular fossa, and so forth) to identify
the right position for PSV. Local anaesthesia will be infil-
trated in sterile fashion into the skin and periosteum of
the clavicle. The location of the puncture will be marked
between the proximal and medial third of the clavicle. A
skin incision can be performed above the puncture
location.
After that, the subclavian vein will be punctured using
the Seldinger technique and a guide wire will be intro-
duced. An introducer sheath will be passed over the
guide wire into the vein. The guide wire will be removed
and the port catheter introduced through the introducer
sheath. Correct position will be checked by X-ray, fluor-
oscopy or intraatrial electrocardiogram. A subcutaneous
pocket will be prepared by blunt preparation on the pec-
toral fascia through the same incision. Alternatively, a
second skin incision can be performed and a subcutane-
ous pocket will then be prepared bluntly on the pectoral
fascia. The port chamber will be fixed on the fascia of
the pectoral muscle with three single non-absorbable su-
tures. Wound closure will be performed in accordance
with the local standards of the trial centres. Correct pos-
ition of the port catheter will be checked again through
X-ray or fluoroscopy (tip of the catheter in the superior
vena cava just at the level of bronchial bifurcation). Flow
for blood withdrawal and infusion will be tested via cu-
taneous puncture (Huber needle). To complete the pro-
cedure the system will be blocked by means of saline,
with or without heparin, according to local standards.
Primary and secondary endpoints
Primary endpoint
The primary endpoint will be the frequency of post-
interventional pneumothorax and haemothorax. Pneumo-
thorax and haemothorax will be defined as the presence
of air or blood in the pleural space, respectively. The rate
of pneumothorax and haemothorax will be assessed two
hours post-implantation by means of a chest X-ray (in in-
spiration) by the responsible physician if PSV was per-
formed. In the event that SCD with or without RT is
successful, a chest X-ray will be performed only in patients
with suspicion or symptoms of pneumothorax or haemo-
thorax (for example dyspnoea), since SCD has no associ-
ated risk of these conditions. A copy of the post-operativepneumothorax and/or haemothorax control radiograph
will be saved in digital form, using radiological image
viewing software (such as Centricity®, GE Healthcare,
Buckinghamshire, United Kingdom), or a copy of the
original radiograph will be archived. The presence of
pneumothorax and haemothorax will be documented
in the case report form (CRF). At follow-up visit three
on day 30, the study nurse will also ask the patient
about further post-operative occurrence of pneumothorax
and haemothorax and check the patient’s documents for
further diagnostic and treatment procedures in this
regard.
Secondary endpoints
Duration of port implantation procedure For the open
strategy, the time from cutaneous incision to last knot of
intracutaneous suture and the time from the patient en-
tering the intervention room until the patient has left,
will be measured. For the closed strategy, the time from
first intervention on the patient (that is, first sonog-
raphy, first radiography or first puncture) to the last
knot of the intracutaneous suture, and the time from the
patient entering the intervention room until the patient
has left, will be measured. Both time measurements will
be documented in the CRF on the day of intervention by
the surgeon or a study nurse.
Subjective tolerability of intervention This is defined
as a subjective rating of the tolerability of the interven-
tion by the patient. It will be assessed on the day of op-
eration, after the intervention has taken place. Patients
will be asked two questions rating the tolerability of the
intervention on a standardised Likert scale (1 = well tol-
erable to 5 = intolerable). Furthermore, the willingness of
the patients to repeat the intervention under the same
conditions will be assessed. The answers will be docu-
mented in the CRF.
Primary success rate Primary success is defined as cor-
rect positioning of the tip of the catheter in the superior
vena cava with the randomised strategy at the intended
side, controlled intra- or post-operatively by radiography,
and correct function of the catheter, checked by blood
sampling and infusion of fluid. Primary success will be
assessed post-operatively by the responsible physician
and documented in the CRF. A copy of the intra-
operative radiograph showing the catheter in the correct
position will be saved in digital form using radiological
image viewing software (for example, Centricity), or a
copy of the original radiograph will be archived.
Thirty-day mortality This is defined as death during
the first 30 days after the operation from causes related
or unrelated to TIVAP implantation. In the event of not
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interview, the study nurse will contact the relatives or
family physician to ask them whether the patient has
died, and if so, the cause of death.Thirty-day morbidity This is defined as the occurrence
of any of the complications listed in Table 1, known
as possible peri- and post-operative complications of
TIVAP implantation leading to deviation from the ex-
pected post-operative course. Peri- and post-operative
complications of port implantation will be recorded with
tick boxes in the CRF on the day of operation and at
visit three (30 days after operation, by telephone ques-
tionnaire) by the surgeon and/or study nurses. All com-
plications will be rated according to the Clavien-Dindo
classification of surgical complications (Table 2) [20]. In
the event of not being able to talk to the patient at the
30-day telephone interview, the study nurse will contact
the relatives or family physician to ask them for informa-
tion regarding the follow-up criteria.Dose rate of radiation This is defined as the product of
dose rate and area of radiation (cGy × cm2). The correct-
ness of documentation will be verified by a study nurse.
The exact value will be documented in the CRF on the
day of intervention.Table 1 Definitions of peri- and post-operative complications
Complication Definition
Intra-operative lesion of nerves Clinical diagnosis an
Dislocation of the catheter and/or the port chamber Radiological finding
Incompatibility of contrast agent Any allergic reaction
Thrombosis Sonographic finding
Post-operative bleeding Clinical diagnosis du
Haematoma Clinical diagnosis, no
Disconnection or breakage of the catheter Radiological findings
Extravasation of injected fluid Radiological findings
Wound infection Clinical diagnosis, wo
Catheter sepsis Two or more of the
Temperature over 38
Heart rate over 90 b
Respiration rate over
PaO2/FiO2 < 200 mm
Total peripheral WBC
regardless of total pe
Plasma C-reactive pr
the port catheter pik
Cutaneous necrosis Clinical diagnosis an
Pinch-off phenomenon Radiological findings
EMG: electromyography; PaCO2: partial pressure of carbon dioxide; PaO2: partial pr
mercury; WBC: white blood cells.Skill of surgeons Surgeons will be classified in the CRF
as follows: 1 to 10, 11 to 25, 26 to 50 or >50 TIVAP im-
plantations. Whether or not surgeons have a board cer-
tificate on the day of intervention will be documented. It
will also be documented whether another experienced
surgeon was called in, and instances of complex or un-
successful primary implantation will be recorded.
Description of trial visits
The specific data to be collected at the trial visits are
presented in Table 3.
Visit one
If a subject is included, the following baseline data will
be recorded in the CRF: gender, age (years), height (cm),
weight (kg), relevant comorbidities (chronic obstructive
pulmonary disease, lung emphysema or asthma), under-
lying malignant disease necessitating TIVAP, current
antibiotic treatment, current CHT, smoking status, alco-
hol abuse, Karnofsky score.
Visit two
Prior to the surgical intervention, patients will be rando-
mised to either the open or closed strategy, and the
treatment assignment will be documented. Furthermore,
the following details will be documented: performed
intervention (SCD or PSV), surgeon’s expertise, durationd/or EMG findings
against a contrast agent needing medical treatment with drugs
s and/or phlebography
ring reoperation
reoperation necessary
, findings after explantation
and/or clinical diagnosis
und has to be reopened and/or antibiotic treatment
following symptoms:
.3°C or under 36°C;
eats per minute;
20 breaths per minute, PaCO2 < 32 mmHg (spontaneous breathing) or
Hg (mechanical ventilation);
count >12 G/L or WBC <4.0 G/L or >10% immature neutrophils (bands),
ripheral WBC count;
otein >2 SD above normal value and positive findings in bacteriology of
e
d/or histological finding
and/or clinical diagnosis
essure of oxygen; FiO2: fraction of inspiratory oxygen; mmHg: millimetres of
Table 2 Clavien-Dindo classification
Grade Definition
Grade I Any deviation from the normal post-operative course without the need for pharmacological treatment or surgical, endoscopic
or radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and
electrolytes, and physiotherapy. This grade also includes wound infections opened at the bedside.
Grade II Requiring pharmacological treatment with drugs other than those allowed for grade I complications. Blood transfusions
and total parenteral nutrition are also included.
Grade III Requiring surgical, endoscopic or radiological intervention.
Grade IIIa Intervention not under general anaesthesia
Grade IIIb Intervention under general anaesthesia
Grade IV Life-threatening complication (including central nervous system complications)* requiring intensive care unit management
Grade IVa Single-organ dysfunction (including dialysis)
Grade IVb Multi-organ dysfunction
Grade V Death
Suffix ‘d’ If the patient is suffering from a complication at the time of discharge, the suffix ‘d’ (for ‘disability’) is added to the grade.
This label indicates the need for follow-up to fully evaluate the complication.
*including brain hemorrhage, ischemic stroke, subarachnoidal bleeding, but excluding transient ischemic attacks.
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rate, rate of pneumothorax and haemothorax (primary
endpoint), serious adverse events (SAE), study port im-
planted (yes or no), peri-operative prophylactic antibiotics
given (yes or no), exact documentation of the executed
procedure and rating of tolerability of intervention.
Visit three
Patients will be called by a study nurse on day 30 post-
operation and asked about SAE and primary and second-
ary endpoints by means of a standardised questionnaire.
All data will be documented in the CRF.
Safety aspects
In the PORTAS-3 trial only SAEs meeting one of the
following criteria will be documented: resulting in death,
is immediately life-threatening, requiring or prolongingTable 3 Data to be collected at trial visits one to three
Visit 1 2 3
Screening Day of
operation
Post-operative
day 30
Inclusion and exclusion criteria,
and written informed consent
X
Baseline demographic data X
Randomisation X
Primary endpoint X X
Tolerability of intervention X X
Duration of procedure X
Primary success rate X
Survival X
Complications X X
Serious adverse events X Xhospitalisation, resulting in persistent or significant disabil-
ity or incapacity and other substantial medical reasons.
From the day the patient has been randomised until
the regular end of trial at 30 days follow-up, or until pre-
mature withdrawal of the patient, all SAE will be docu-
mented on an SAE form, available in the investigator
site file. Assessment of SAE will be based on surgical
findings and the clinical course of the patient, and will
be carried out by the investigators at the participating
trial centres. They will be furnished with written recom-
mendations on how to assess the causal connection with
trial interventions. An SAE will have to be reported to
the principal investigator by the attending physician
within 24 hours after it becomes known.
Study-specific serious adverse events
As it can be anticipated that many events fulfilling the
SAE criteria will be caused by the underlying disease or
treatment and will not be related to trial intervention
(for example, hospitalisation due to neutropenic fever
after CHT), only SAEs not related to the underlying dis-
ease or treatment will have to be reported. Anticipated
SAEs due to the underlying disease that do not have to
be reported include the following:
1. hospitalisation due to progress of underlying disease;
2. hospitalisation due to bone marrow toxicity of CHT,
including:
2a. neutropenic fever,
2b. anaemia requiring transfusion of red
blood cell concentrates,
2c. haemorrhagic events necessitating intervention/
transfusion due to thrombocytopenia;
3. hospitalisation due to severe nausea, vomiting and
exsiccosis caused by CHT;
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renal function related to CHT.
The occurrence of pneumothorax and haemothorax
will be documented as SAEs for safety reasons.
Analysis
Hypotheses
The primary endpoint is the occurrence of pneumo-
thorax and haemothorax after implantation of a TIVAP.
To formalise the statistical approach, the following nota-
tion will be used: popen/pclosed, that is, rate of occurrence
of pneumothorax and haemothorax after implantation of
a TIVAP in the open-strategy group (open)/closed-
strategy group (closed).
The following two-sided test problem is defined:
H0 : popen ¼ pclosedversus H1 : popen≠pclosed
Analysis sets
Each patient’s allocation to the different analysis popula-
tions (full analysis set (FAS) according to the intention-
to-treat (ITT) principle, per protocol (PP) analysis set
and safety analysis set) will be defined prior to the ana-
lysis. The allocation will be documented in the statistical
analysis plan. During the data review, deviations from
the protocol will be assessed as ‘minor’ or ‘major’. Major
deviations from the protocol will lead to the exclusion of
a patient from the PP analysis set.
Testing the primary hypothesis
The null hypothesis H0 will be assessed by testing the
intervention effect in a logistic regression model that
takes into account the covariates ‘intervention’ (open or
closed strategy), ‘skill of surgeon’ (board certificate yes or
no, number of TIVAP implanted), ‘body mass index’ (kg/
m2), ‘Karnofsky index’ (percentage) ‘gender’ (female or
male) and ‘age’ (years). A two-sided type I error rate of
α = 0.05 will be applied. Confirmatory analysis will be
primarily based on the FAS, which is consistent with the
ITT principle by including all patients randomised to
the two groups. This approach reflects the idea that the
study should match the conditions in clinical practice as
closely as possible.
Missing data
As explained above, it can be assumed that there will be
no missing values with respect to the primary endpoint.
If missing values occur, they will be replaced by means
of the ICA-r method described by Higgins et al. [21].
Further analyses
In addition to the evaluation of the FAS a PP analysis
will be performed including all randomised patientswithout major protocol violations. The secondary vari-
ables will be analysed descriptively by tabulation of the
measures of the empirical distributions. According to
the scale level of the variables, means, standard deviations,
medians and first and third quartiles, as well as minimum
and maximum or absolute and relative frequencies will be
reported. Descriptive P values of the corresponding statis-
tical tests comparing the treatment groups and associated
95% confidence intervals will be given.
The homogeneity of the treatment groups will be de-
scribed by comparison of the demographic data and the
baseline values. Statistical methods will be used to assess
data quality and the homogeneity of the intervention
groups. A safety analysis will be conducted and will in-
clude calculation and comparison of frequencies and
rates of SAEs. All analyses will be done using SAS
version 9.1 or higher (SAS Institute Inc., Cary, North
Carolina, USA).
Participating centres
The following centres are planned to participate in the
PORTAS-3 trial: Ansbach Hospital, Berlin Park Hospital
Weißensee, Municipal Hospital Braunschweig, University
Hospital Dresden, Evangelical Hospital Gelsenkirchen,
Eichert Hospital/Göppingen Rural District Hospitals, Uni-
versity Hospital Heidelberg, Salem Hospital Heidelberg,
Heidenheim Hospital, Ingolstadt Hospital, Memmingen
Hospital, Lukas Hospital Neuss, Esslingen District Hos-
pitals/Nürtingen Hospital, Passau Hospital, University
Hospital Regensburg, “Gesundheitszentren Rhein-Neckar”
Hospital Sinsheim and Joseph Hospital Warendorf.
Trial organisation
All patients scheduled for TIVAP implantation at one of
the participating centres will be screened for eligibility
by the respective study centre, and the results will be
documented in a screening log. The participating centres
perform approximately 3,882 TIVAP implantations per
year (estimated from preliminary screening over a two-
month period). Therefore, a recruitment period of
18 months is expected to be sufficient to randomise
1,154 patients. Independent data management and
statistical analyses will be performed by the Institute of
Medical Biometry and Informatics of the University of
Heidelberg, in compliance with a pre-specified statistical
analysis plan.
Ethical and legal aspects
All procedures set out in the protocol pertaining to the
conduct, evaluation and documentation of the PORTAS-
3 trial are designed to ensure that all persons involved in
the trial abide by the principles of Good Clinical Practice
[22] and the ethical principles described in the current
revision of the Declaration of Helsinki [23]. The trial will
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tory requirements (such as the German Federal Data
Protection Act, 1990 [last change 25 February 2015]).
The protocol has already been approved by the inde-
pendent ethics committee (IEC) of the medical faculty of
the University of Heidelberg, and secondary approval of
the corresponding ethical bodies of all other participat-
ing centres has been obtained. A list containing the
names and reference numbers of all ethical bodies is
provided as an additional file (Additional file 1). Any
amendments will be submitted to all of the IEC. The
IEC will also be informed of the end of the trial. The trial
protocol has been issued in accordance with the recom-
mendations of the CONSORT and Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
guidelines (Additional file 2) [24,25].
Discussion
TIVAP implantation is one of the most common general
surgical procedures [3] and is performed routinely by
either SCD or PSV. However, only few randomised con-
trolled trials [4,6,9,17] and no multicentre trials com-
pared these techniques for their potential risks and
benefits. The aim of the PORTAS-3 trial is to compare a
primary open strategy (SCD with RT if necessary; PSV if
the aforementioned fail) to a primary closed strategy
(PSV; SCD if PSV fails) in regard to the frequency of
post-operative pneumothorax and haemothorax, with
the hypothesis that the open strategy is able to signifi-
cantly reduce the risk of pneumothorax and haemothorax
occurrence.
The PORTAS-3 trial is designed as a pragmatic trial,
since the objective is to depict the real medical treatment
situation. Therefore, just some key steps of the interven-
tions are predefined, and the rest can be performed
according to local practice of the centres. For instance,
in PSV either sonography, fluoroscopy or anatomical
landmarks can be used for guidance of the puncture.
Some authors suggested that sonographic guidance
should be the method of choice for vascular cannula-
tion due to improved safety [26]. Even though ultra-
sound is widely available nowadays, this still does not
represent comprehensive clinical practice in a lot of
hospitals, and a recent Cochrane review on ultrasound
guidance for subclavian vein catheterization [27] could
only show a reduced risk of arterial cannulation, and
no reduction for other complications like pneumo-
thorax and haemothorax.
The results of the PORTAS-3 trial will be applicable to
a wide range of patients and could influence future
guidelines and decision-making. Healthcare costs might
be reduced by the reduction of complications and neces-
sary treatment and hospitalization for these complica-
tions. Furthermore, required treatment of patients (forexample, with CHT) will not be delayed by potential
complications.
Trial status
The PORTAS-3 trial has already started recruitment of
patients in November 2014 and recruitment is currently
ongoing and is expected to be complete in the first quarter
of 2016.
Additional files
Additional file 1: Ethical approvals: List of participating centres
with corresponding ethics committees and reference numbers of
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which this point is addressed.
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